middle.news
OncoSil Medical Boosts Sales 53% as TRIPP-FFX Trial Opens New Market Pathways
8:42am on Thursday 30th of July, 2026 AEST
•
Healthcare
Read Story
OncoSil Medical Boosts Sales 53% as TRIPP-FFX Trial Opens New Market Pathways
8:42am on Thursday 30th of July, 2026 AEST
Key Points
53% unit sales growth and 44% revenue increase in FY26
TRIPP-FFX trial met co-primary endpoints supporting label expansion
FDA Humanitarian Device Exemption application enters final review
TGA approval enables Australian commercial launch
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Oncosil Medical (ASX:OSL)
OPEN ARTICLE